NRG-LU004

Report Based on Data Through: 04/30/2019

Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

Registration: Institution-determined PD-L1 expression ***using Dako 22C3 IHC antibody*** platform. The first 3 patients with PD-L1 expression of ≥50% will be registered to Cohort 1 and the following 3 patients with PD-L1 expression of ≥50% will be registered to Cohort 2.

LEAD-IN SCHEMA (Initial Safety Schedules)

Cohort 1, n=3
MEDI4736 (durvalumab)[†] **q4 weeks** x 13 doses
+ ACRT 60 Gy in 15 fx x 3 weeks (weeks 1-3)

Cohort 2, n=3
MEDI4736 (durvalumab)[†] **q4 weeks** x 13 doses
+ standard RT 60 Gy in 30 fx x 6 weeks (weeks 1-6)

[†] MEDI4736 (durvalumab) begins 2 weeks (Day -14) before RT (+/- 48 hours); see Section 5.1 for dosing details

EXPANSION COHORTS

After completing one of the Initial Safety Schedules of concurrent RT+MEDI4736 (durvalumab):

- If Cohort 1 only is deemed safe, all patients will be registered to Cohort 3.
- If Cohort 2 only is deemed safe, all patients will be registered to Cohort 4.
- **If both Cohorts 1 and 2 are deemed safe, patients will be randomized to either Cohort 3 or Cohort 4 with 1:1 randomization.**



† MEDI4736 (durvalumab) begins 2 weeks (Day -14) before RT (+/- 48 hours); see Section 5.1 for dosing details

Study Chairs:	Steven H. Lin, MD, PhD	(Principal Investigator/ Radiation Oncology)
	Anne Tsao, MD	(Medical Oncology)
	Martin Edelman, MD, FACP	(Medical Oncology)
	Anthony Doemer, MS, DABR	(Medical Physics)
	Charles B. Simone II, MD	(Translational)

Protocol Statisticians: Stephanie Pugh, PhD
Rebecca Paulus, BS

Research Associates: Jeff Serianni, BS
Amy Krystkiewicz, RN

Dosimetrist: Jennifer Presley, R.T. (R)(M)(T)

Activated: January 4, 2019

Status: Accruing

- **Study Description**

  NRG-LU004 is a phase I trial to assess the safety and feasibility of MEDI4736 (durvalumab) and RT that is split into 2 parts. In the initial safety part, 3 patients will enroll to the ACRT + MEDI4736 (durvalumab) arm, with a mandatory toxicity evaluation period of 90 days from the start of radiation therapy. After the first 3 patients are enrolled onto the ACRT, 3 patients will be enrolled to the standard radiation + MEDI4736 (durvalumab) arm with a mandatory toxicity evaluation of 8 weeks from the start of radiation therapy. Once all patients have been assessed for toxicity, the expansion part of this study will enroll 9 patients each to the arm(s) that is/are deemed safe. If both arms are deemed safe, then a total of 18 patients will be randomized to receive ACRT + MEDI4736 (durvalumab) or standard radiation + MEDI4736 (durvalumab). If only one of the two arms is deemed safe, then only that arm will enroll 9 additional patients. If neither arm is deemed safe, then the study will not continue onto the expansion part. Eligible patients have stage II-III unresectable or inoperable, non-metastatic non-small cell lung cancer (NSCLC) with a pathological diagnosis of PD-L1 high

expressing tumor (>50%). The primary endpoint is treatment-related serious adverse events assessed using CTCAE v5.0.

- **Patient Accrual**
  Accrual was activated on January 4, 2019. No patients were accrued as of April 30, 2019.